The Texas Rangers added another proven veteran to their improved starting rotation.
Texas native Nathan Eovaldi has agreed to sign a two-year deal with the Rangers that carries an option for an additional year. The team announced the deal after the right-hander completed a physical for Texas.
Eovaldi comes just 3 1/2 weeks after the Rangers signed two-time National League Cy Young Award winner Jacob deGrom in free agency.
A person familiar with the deal said Eovaldi will earn $34 million guaranteed, his salary totaling $16 million in 2023 and 2024, with a $2 million signing bonus payable later. The person spoke on condition of anonymity because the team did not release details of the deal, which includes a $20 million player option for 2025 if Eovaldi totals 300 innings over the next two seasons.
“I am excited that we have added another standout pitcher to the rotation in Nathan Eovaldi,” Rangers general manager Chris Young said in a statement. “Nathan has great quality and an unmatched work ethic that will bring a veteran’s presence to the staff.”
Eovaldi has pitched for five teams in 11 major league seasons. He spent four and a half years with the Boston Red Sox. He went 6–3 with a 3.87 ERA in 20 starts in 2022 after going on the disabled list twice (lower back inflammation and shoulder problems). He finished 11–9 with a 3.75 ERA in 32 starts in 2021, when he was selected to the All-Star Game for the first time and finished fourth in AL Cy Young voting.
The Houston native is 67-68 with a 4.16 ERA in 240 games (221 starts) with Boston, Miami, Los Angeles Dodgers, New York Yankees and Tampa Bay.
DeGrom agreed to sign for five years and $185 million last month before the winter meetings.
Texas also signed Andrew Heaney for two years in free agency worth $25 million, acquired Jake Odorizzi in a trade with Atlanta and retained star lefty Martin Perez for a qualifying offer of $19.65 million. The Rangers last winter signed right-hander John Gray to a four-year, $56 million deal, as well as adding infielders Corey Seager and Markus Semin for nearly $500 million each.